Results 121 to 130 of about 15,615 (185)

Effects of Unilateral High Frequency Stimulation of the Subthalamic Nucleus on Risk-avoidant Behavior in a Partial 6-hydroxydopamine Model of Parkinson's Disease. [PDF]

J Integr Neurosci
Hillan SG, Asp AJ, Pramanik LB, Mukerjee AA, Mulder CB, Lujan WD, Silvernail JL, Chang SY, Boschen SL, Lujan JL.   +9 more
europepmc   +1 more source

Role of Nitric Oxide Modulators in Neuroprotective Effects of Mangiferin in 6-Hydroxydopamine-induced Parkinson's Disease in Rats. [PDF]

Ann Neurosci
Tiwari PC, Chaudhary MJ, Pal R, Nath R.
europepmc   +1 more source

Sustained Systemic Antioxidative Effects of Intermittent Theta Burst Stimulation beyond Neurodegeneration: Implications in Therapy in 6-Hydroxydopamine Model of Parkinson's Disease. [PDF]

Antioxidants (Basel)
Zeljkovic Jovanovic M, Stanojevic J, Stevanovic I, Ninkovic M, Nedeljkovic N, Dragic M.   +5 more
europepmc   +1 more source

The effect of inhibiting hindbrain A2 noradrenergic neurons by 6-Hydroxydopamine on lipopolysaccharide-treated male rats autistic animal model. [PDF]

Saudi Pharm J
Alhamami HN, Albogami AM, Algahtani MM, Alqinyah M, Alanazi WA, Alasmari F, Alhazzani K, Alanazi AZ, Alassmrry YA, Alhamed AS.   +9 more
europepmc   +1 more source

Increase in adrenal dopamine following 6-hydroxydopamine

Journal of Pharmacy and Pharmacology, 1974
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Prevention of 6-hydroxydopamine neurotoxicity

European Journal of Pharmacology, 1975
1-Phenyl-3-(2-thiazolyl)-2-thiourea (PTTU) prevented the neurotoxic actions of 6-hydroxydopamine on adrenergic nerves in the mouse atrium and iris. This is the first reported 6-hydroxydopamine antagonist that does not act by blocking uptake of catecholamines into nerve terminals. PTTU also prevented the diabetogenic action of alloxan.
Catherine Mytilineou, R Heikkila, C Mytilineou   +2 more
exaly   +3 more sources

6-Hydroxydopamine, a new oxidation mechanism

European Journal of Pharmacology, 1972
Abstract Electrochemical and chemical studies, supported by EPR, NMR and UV evidence, show that 6-hydroxydopamine does not oxidize in vitro at physiological pH to the cyclized indoline (aminochrome) as previously believed. The implications of these results to the chemical sympathectomy actions of 6-hydroxydopamine are discussed.
R N Adams, R N Adams
exaly   +3 more sources

Behavioral pharmacology of 6-hydroxydopamine

Life Sciences, 1973
Publisher Summary This chapter reviews the behavioral pharmacology of 6-hydroxydopamine. The ability of 6-hydroxydopamine (6-HDA) to produce a specific degeneration of central catecholamine-containing neurons offers a unique opportunity to study the consequences of loss of these neurons on the performance of a conditioned response. The 6-HDA treatment
R.I. Schoenfeld, M.J. Zigmond
openaire   +1 more source

Central effects of 6-hydroxydopamine

Physiology & Behavior, 1971
Abstract The central effects of 6-hydroxydopamine (6-OHDA) injected intracerebrally in mice and intracisternally in rats have been studied. Mice treated with 100 μg of the drug were sedated and lethargic, with reduced spontaneous activity, for periods of up to 8 days after injection. For a similar period, the response to amphetamine consisted only of
A S, De Carolis, H, Ziegler, P, Del Basso, V G, Longo   +3 more
openaire   +2 more sources